Elranatamab FDA Approval for Multiple Myeloma

Elranatamab received accelerated approval from the U.S. Food and Drug Administration in August 2023 for the treatment of adults with relapsed or refractory multiple myeloma who have already been through at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.¹ The approval was based on response rates and how long those responses lasted, not on long-term survival data, which means continued approval hinges on confirmatory trials still underway. For a cancer that becomes progressively harder to treat with each relapse, a new option at this late stage matters, but the story behind the drug, its strengths, its limits, and the open questions around it, is worth understanding in detail.

How Elranatamab Works

Elranatamab is a bispecific antibody, meaning it has two arms that each grab a different target. One arm latches onto BCMA (B-cell maturation antigen), a protein found on the surface of myeloma cells. The other arm grabs CD3, a protein on T cells, which are the immune system’s main cancer-killing soldiers.² By physically bridging a T cell and a myeloma cell, elranatamab forces the T cell into close contact with its target and triggers it to kill. The drug essentially hijacks the patient’s own immune system and redirects it toward cancer cells, regardless of whether those T cells would have recognized the myeloma on their own.³

BCMA is a useful target because it is highly expressed on myeloma cells but found on very few other cell types in the body. That selectivity reduces the risk of off-target damage to healthy tissue, though it does not eliminate immune-related side effects entirely, as we’ll see with cytokine release syndrome. Elranatamab is given as a subcutaneous injection, not an IV infusion, which shapes both how the drug is absorbed and how patients experience treatment.

The Clinical Evidence Behind Approval

The pivotal trial that supported the FDA decision was MagnetisMM-3, a phase 2 study enrolling patients with relapsed or refractory multiple myeloma who had not received prior BCMA-directed therapy. In the registrational population, elranatamab produced an overall response rate of about 61%, with a median progression-free survival of 17.2 months and a median overall survival of 24.6 months.⁴ For patients who had already cycled through multiple drug classes and were running out of options, a response rate above 60% was a meaningful signal.

At an earlier data cut, the median duration of response among responders had not yet been reached, and the probability of maintaining a response at 15 months was roughly 72%.⁵ With longer follow-up, updated data showed that the probability of maintaining a response at 24 months was about 67%, and patients who achieved a complete response or better fared even better, with roughly 88% still in response at two years.⁶ In other words, the deeper the response, the more durable it tended to be.

A U.S.-specific subgroup analysis from MagnetisMM-3 reported an even higher objective response rate of 66%, with about 43% of patients achieving a complete response or better at a median follow-up of nearly 40 months.⁷ These are encouraging numbers, but it is worth keeping in mind that accelerated approval rests on surrogate endpoints like response rate, not on proven survival benefit. Confirmatory data will need to come from larger, randomized trials.

Managing Cytokine Release Syndrome and Other Side Effects

The most recognized side effect of bispecific antibodies like elranatamab is cytokine release syndrome, or CRS. When the drug activates T cells in bulk, those T cells release a flood of signaling molecules that can cause fever, low blood pressure, and in severe cases, organ dysfunction. In MagnetisMM-3, about 58% of patients experienced some degree of CRS, but no cases reached grade 3 or higher, meaning none were life-threatening.⁸ The vast majority of CRS events were mild, with fever that resolved within a couple of days.

CRS risk is highest with the initial doses, which is why elranatamab uses a step-up dosing strategy. Patients receive two lower priming doses before reaching the full treatment dose. Early dose-escalation studies helped establish this approach by showing that CRS incidence and severity increased sharply with higher single doses and with intravenous administration.⁹ The switch to subcutaneous delivery and the gradual ramp-up were direct responses to those findings. Most CRS events occurred on the same day as dosing, with a median onset of about one day and resolution within a few days.

Neurological side effects, referred to as immune effector cell-associated neurotoxicity syndrome (ICANS), were much less common, occurring in about 3-6% of patients. In MagnetisMM-3, all ICANS cases were grade 1 or 2 and were managed with corticosteroids and supportive care.¹⁰ That said, rare severe cases have been documented outside the trial setting, which underscores the importance of close monitoring during the step-up period. Blood count drops, particularly neutropenia, anemia, and low platelets, are also common and require regular monitoring and sometimes dose adjustments or growth factor support.

Spacing Out Doses Over Time

One practical question for patients on a therapy they may take indefinitely is whether dosing can be reduced over time. The standard regimen starts with weekly subcutaneous injections. For patients who achieved a confirmed response after at least six months of weekly dosing, MagnetisMM-3 allowed a switch to every-other-week (Q2W) injections. Among those who switched, 80% maintained or improved their response at least six months after the change, and 40% actually deepened their response, including 38% who improved to a complete response or better.¹¹ The rate of serious side effects also dropped after switching to less frequent dosing.

Updated data confirmed that median progression-free survival for the overall population was 17.2 months and that the switch to Q2W did not appear to undermine long-term disease control among established responders.¹² Researchers have also modeled the feasibility of stretching dosing to once monthly (Q4W) for patients in deep, sustained remission, though clinical data on that schedule are still early.¹³ For patients, the prospect of fewer clinic visits and fewer injections while staying in remission is a significant quality-of-life gain.

Effectiveness After Prior BCMA-Directed Therapy

Because BCMA is such an attractive target, several therapies now aim at it, including CAR-T cell products and antibody-drug conjugates. A growing number of patients arrive at elranatamab having already received one of these. The obvious question is whether elranatamab still works when the cancer has already seen and potentially adapted to a BCMA-directed treatment.

In the phase 1 MagnetisMM-1 trial, about 54% of patients with prior BCMA-directed therapy achieved a confirmed response to elranatamab, including several complete responses.¹⁴ A larger pooled analysis across MagnetisMM studies found an overall response rate of about 45% in BCMA-exposed patients, with median progression-free survival of 4.8 months. Among those previously treated with CAR-T cells specifically, the response rate was roughly 53%.¹⁵ These response rates are lower than those seen in BCMA-naïve patients, as expected, but the drug still produced meaningful activity in a population with very few remaining options. No new safety signals emerged in the BCMA-exposed group compared to the naïve population.

Elranatamab Compared to Teclistamab and CAR-T Therapy

Teclistamab is the other BCMA-targeting bispecific antibody approved for relapsed or refractory myeloma, which makes the comparison between the two unavoidable. No head-to-head randomized trial has been completed, so the available evidence comes from indirect comparisons and real-world data. A matching-adjusted indirect comparison suggested that elranatamab had a better objective response rate and progression-free survival than teclistamab.¹⁶ However, a real-world propensity score-matched study found no significant difference between the two drugs in time to next treatment or three-year overall survival.¹⁷

Where the two drugs do differ clearly is in their side-effect profiles. In the real-world comparison, CRS was more common with elranatamab (about 45% versus 27% for teclistamab), while severe neutropenia was more frequent with teclistamab (about 85% versus 75%).¹⁸ Infection rates and ICANS were similar between the two. Teclistamab may have had an edge in certain subgroups, including patients with very low platelet counts and those beyond five prior lines of therapy. The practical takeaway for now is that the two bispecific antibodies appear broadly comparable in effectiveness, with the choice often hinging on side-effect considerations and logistical factors like dosing schedule.

The comparison with CAR-T cell therapy adds another dimension. CAR-T involves collecting a patient’s own T cells, engineering them in a lab to target BCMA, and infusing them back. It is a one-time treatment but requires manufacturing time, which creates a waiting period during which the myeloma can progress. A real-world comparison found that CAR-T therapy was associated with a 64% lower risk of death compared to bispecific antibodies as a class, but also with higher rates of CRS, ICANS, neutropenia, and thrombocytopenia.¹⁹ CAR-T therapy appears to produce deeper and more durable responses on average, but at the cost of more intense upfront toxicity, limited availability at specialized centers, and the logistical hurdle of the manufacturing delay. Bispecific antibodies like elranatamab can be started immediately and are available at a wider range of treatment sites.

How Resistance Develops

Not all patients respond to elranatamab, and some who do respond eventually relapse. Understanding why helps guide the development of next steps. One key mechanism involves genetic changes in the BCMA gene itself. Researchers have identified specific mutations in BCMA that can make myeloma cells invisible to bispecific antibodies. In laboratory studies, certain mutations (such as one called p.Arg27Pro) made cells resistant to both teclistamab and elranatamab, while other mutations (like p.Ser30del) caused resistance to teclistamab but not to elranatamab.²⁰ This is an important nuance: resistance to one BCMA-targeting drug does not necessarily mean resistance to all of them, because the drugs bind to different parts of the BCMA protein.

Beyond target mutations, myeloma cells can also downregulate BCMA expression altogether, reducing the number of molecules available for elranatamab to grab. T-cell exhaustion is another factor. Over time, the relentless stimulation from a continuously dosed bispecific antibody can wear out the very T cells the drug depends on. This is an active area of research, and strategies like treatment holidays or combination regimens that support T-cell fitness are being explored as potential countermeasures.

Moving Toward Earlier Lines of Therapy

The current approval is limited to patients who have exhausted at least four prior lines of therapy, but trials are already testing elranatamab much earlier in the disease course. MagnetisMM-5 is a phase 3, randomized, open-label trial comparing elranatamab as a single agent, elranatamab combined with daratumumab, and a standard triplet regimen (daratumumab, pomalidomide, and dexamethasone) in patients who have had as few as one prior line of therapy.²¹ If the drug proves effective earlier, it could shift the treatment landscape meaningfully, because patients earlier in their disease tend to have healthier immune systems and less damaged bone marrow, which may translate into better responses and fewer complications.

The combination with daratumumab is particularly interesting because it pairs two different modes of immune attack against myeloma: bispecific T-cell engagement and antibody-dependent destruction via the anti-CD38 pathway. Whether this translates into additive benefit without additive toxicity is exactly what the trial aims to answer. Ongoing studies and real-world experience will be critical for defining where elranatamab fits among the growing roster of options available to myeloma patients.²²

What Patients Report About Life on Treatment

Clinical trials often focus on tumor shrinkage and survival curves, but what matters just as much to patients is how they feel day to day. Patient-reported outcome data from MagnetisMM-3 showed that elranatamab maintained or improved quality of life in heavily pretreated patients, with early improvements in pain, disease symptoms, and patients’ outlook on their future health.²³ These improvements held regardless of whether patients had received prior BCMA-directed therapy.

When compared against real-world physician-choice therapies for triple-class refractory myeloma, patients on elranatamab reported greater improvements in general quality of life, disease symptoms, and their overall impression of health status.²⁴ This is meaningful context for a population where the alternative therapies are often poorly tolerated and have modest efficacy. A drug that not only controls the cancer but also lets patients feel better in the process changes the calculation when weighing treatment options.

The Outpatient Administration Question

Because CRS risk is highest during the step-up dosing period, manufacturers recommend that those initial doses be given in an inpatient hospital setting where adverse events can be managed quickly. In practice, this creates a bottleneck: inpatient beds are expensive, inconvenient for patients, and limited in availability, which can restrict access to the drug entirely at some treatment centers. A growing number of community oncology practices have begun administering the step-up doses in an outpatient setting, developing protocols for close monitoring, rapid intervention, and patient selection that attempt to balance safety against practicality.²⁵ More data on the feasibility and safety of outpatient step-up administration are needed before this approach becomes standard, but the direction of travel is clear: the field is working to make bispecific antibodies easier to deliver without compromising patient safety.

Once past the step-up phase, ongoing maintenance doses are already given on an outpatient basis, typically as a quick subcutaneous injection. The shift to every-other-week dosing for responders further reduces the clinic visit burden. For patients living in rural areas or far from major medical centers, the accessibility of a subcutaneous injection compared to the specialized manufacturing and infusion infrastructure required for CAR-T cell therapy is a real advantage, even if the long-term efficacy comparison may favor CAR-T in certain populations. The pharmacokinetics of the subcutaneous formulation show roughly 56% bioavailability, with generally proportional drug levels across the dose range used clinically.²⁶ The predictable absorption profile is part of what makes the subcutaneous route workable for routine outpatient care.